Ser856
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser856  -  FLI (human)

Site Information
NAEAVLQsPGLsGkV   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 452779

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 16 , 17 , 18 , 19 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 )
Disease tissue studied:
bone cancer ( 37 ) , osteosarcoma ( 37 ) , breast cancer ( 8 , 17 , 18 ) , breast ductal carcinoma ( 8 ) , HER2 positive breast cancer ( 2 ) , luminal A breast cancer ( 2 ) , luminal B breast cancer ( 2 ) , breast cancer, surrounding tissue ( 2 ) , breast cancer, triple negative ( 2 , 8 ) , cervical cancer ( 38 ) , cervical adenocarcinoma ( 38 ) , leukemia ( 21 , 22 , 48 ) , acute myelogenous leukemia ( 21 ) , chronic myelogenous leukemia ( 48 ) , T cell leukemia ( 22 ) , lung cancer ( 6 , 12 , 18 , 29 ) , non-small cell lung cancer ( 18 ) , non-small cell lung adenocarcinoma ( 6 , 12 , 29 ) , ovarian cancer ( 8 ) , melanoma skin cancer ( 5 )
Relevant cell line - cell type - tissue:
'stem, embryonic' ( 41 ) , 293 (epithelial) [ADRB1 (human), no information, overexpresses human beta1-adrenergic (ß1AR- HEK293)] ( 49 ) , 293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 33 ) , 293 (epithelial) ( 42 ) , 293E (epithelial) ( 28 ) , 786-O (renal) [VHL (human), transfection] ( 4 ) , 786-O (renal) ( 4 ) , A498 (renal) ( 35 ) , A549 (pulmonary) ( 13 ) , breast ( 2 , 8 ) , BT-20 (breast cell) ( 18 ) , BT-549 (breast cell) ( 18 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 19 ) , Flp-In T-Rex-293 (epithelial) ( 19 ) , GM00130 (B lymphocyte) ( 34 ) , H2009 (pulmonary) ( 18 ) , H2077 (pulmonary) ( 18 ) , H2887 (pulmonary) ( 18 ) , H322M (pulmonary) ( 18 ) , HCC1359 (pulmonary) ( 18 ) , HCC1937 (breast cell) ( 18 ) , HCC2279 (pulmonary) ( 18 ) , HCC366 (pulmonary) ( 18 ) , HCC4006 (pulmonary) ( 18 ) , HCC78 (pulmonary) ( 18 ) , HCC827 (pulmonary) ( 18 ) , HCT116 (intestinal) ( 43 ) , HeLa (cervical) ( 7 , 16 , 23 , 32 , 39 , 43 , 47 , 49 , 51 , 52 , 53 ) , HeLa S3 (cervical) [PLK1 (human), knockdown, Tet-inducible PLK1 siRNA] ( 30 ) , HeLa S3 (cervical) ( 30 , 38 , 46 ) , HOP62 (pulmonary) ( 18 ) , HUES-7 ('stem, embryonic') ( 40 ) , HUES-9 ('stem, embryonic') ( 31 ) , Jurkat (T lymphocyte) ( 14 , 24 , 25 , 26 , 27 , 36 , 44 , 45 , 50 ) , K562 (erythroid) ( 16 , 39 , 48 ) , KG-1 (myeloid) ( 21 ) , Kit225 (T lymphocyte) ( 22 ) , LCLC-103H (pulmonary) ( 18 ) , liver ( 10 ) , LOU-NH91 (squamous) ( 18 ) , lung ( 12 ) , MCF-7 (breast cell) ( 18 ) , MDA-MB-231 (breast cell) ( 18 ) , MDA-MB-468 (breast cell) ( 18 ) , NCI-H1395 (pulmonary) ( 18 ) , NCI-H1568 (pulmonary) ( 18 ) , NCI-H157 (pulmonary) ( 18 ) , NCI-H1666 (pulmonary) ( 18 ) , NCI-H2030 (pulmonary) ( 18 ) , NCI-H2172 (pulmonary) ( 18 ) , NCI-H322 (pulmonary) ( 18 ) , NCI-H460 (pulmonary) ( 18 , 43 ) , NCI-H520 (squamous) ( 18 ) , NCI-H647 (pulmonary) ( 18 ) , ovary ( 8 ) , PANC-1 (pancreatic) [PRP4 (human), knockdown, Lentiviral introduced doxycycline-inducible PRP4 shRNA] ( 11 ) , PANC-1 (pancreatic) ( 11 ) , PC9 (pulmonary) ( 6 , 18 ) , PC9-IR (pulmonary) ( 6 ) , SH-SY5Y (neural crest) [LRRK2 (human), transfection, over-expression of LRRK2(G2019S)] ( 9 ) , SKBr3 (breast cell) ( 17 ) , U-1810 (pulmonary) ( 29 ) , U2OS (bone cell) ( 37 ) , Vero E6-S ('epithelial, kidney') ( 1 ) , WM239A (melanocyte) ( 5 )

Upstream Regulation
Regulatory protein:
PRP4 (human) ( 11 )
Treatments:
nocodazole ( 38 )

References 

1

Bouhaddou M, et al. (2020) The Global Phosphorylation Landscape of SARS-CoV-2 Infection. Cell
32645325   Curated Info

2

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

3

Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610
27184836   Curated Info

4

Malec V, Coulson JM, Urbé S, Clague MJ (2015) Combined Analyses of the VHL and Hypoxia Signaling Axes in an Isogenic Pairing of Renal Clear Cell Carcinoma Cells. J Proteome Res 14, 5263-72
26506913   Curated Info

5

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

6

Tsai CF, et al. (2015) Large-scale determination of absolute phosphorylation stoichiometries in human cells by motif-targeting quantitative proteomics. Nat Commun 6, 6622
25814448   Curated Info

7

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

8

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

9

Luerman GC, et al. (2014) Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1. J Neurochem 128, 561-76
24117733   Curated Info

10

Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62
24275569   Curated Info

11

Gao Q, et al. (2013) Evaluation of cancer dependence and druggability of PRP4 kinase using cellular, biochemical, and structural approaches. J Biol Chem 288, 30125-38
24003220   Curated Info

12

Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96
23911959   Curated Info

13

Kim JY, et al. (2013) Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A 110, 12414-9
23836654   Curated Info

14

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

15

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

16

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

17

Imami K, et al. (2012) Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways. Mol Cell Proteomics 11, 1741-57
22964224   Curated Info

18

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

19

Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70
22496350   Curated Info

20

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

21

Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56
22115753   Curated Info

22

Osinalde N, et al. (2011) Interleukin-2 signaling pathway analysis by quantitative phosphoproteomics. J Proteomics 75, 177-91
21722762   Curated Info

23

Grosstessner-Hain K, et al. (2011) Quantitative phospho-proteomics to investigate the polo-like kinase 1-dependent phospho-proteome. Mol Cell Proteomics 10, M111.008540
21857030   Curated Info

24

Mulhern D (2011) CST Curation Set: 12701; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSPX(I/L/M/V)
Curated Info

25

Mulhern D (2011) CST Curation Set: 12702; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSPX(I/L/M/V)
Curated Info

26

Mulhern D (2011) CST Curation Set: 12572; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSPX(I/L/M/V)
Curated Info

27

Mulhern D (2011) CST Curation Set: 12571; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSPX(I/L/M/V)
Curated Info

28

Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22
21659604   Curated Info

29

Ståhl S, et al. (2011) Phosphoproteomic profiling of NSCLC cells reveals that ephrin B3 regulates pro-survival signaling through Akt1-mediated phosphorylation of the EphA2 receptor. J Proteome Res 10, 2566-78
21413766   Curated Info

30

Santamaria A, et al. (2011) The Plk1-dependent phosphoproteome of the early mitotic spindle. Mol Cell Proteomics 10, M110.004457
20860994   Curated Info

31

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info

32

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

33

Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53
20363803   Curated Info

34

Bennetzen MV, et al. (2010) Site-specific phosphorylation dynamics of the nuclear proteome during the DNA damage response. Mol Cell Proteomics 9, 1314-23
20164059   Curated Info

35

Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62
20071362   Curated Info

36

Possemato A (2010) CST Curation Set: 9696; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: YXp[ST]
Curated Info

37

Raijmakers R, et al. (2010) Exploring the human leukocyte phosphoproteome using a microfluidic reversed-phase-TiO2-reversed-phase high-performance liquid chromatography phosphochip coupled to a quadrupole time-of-flight mass spectrometer. Anal Chem 82, 824-32
20058876   Curated Info

38

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info

39

Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808
19651622   Curated Info

40

Van Hoof D, et al. (2009) Phosphorylation dynamics during early differentiation of human embryonic stem cells. Cell Stem Cell 5, 214-26
19664995   Curated Info

41

Brill LM, et al. (2009) Phosphoproteomic analysis of human embryonic stem cells. Cell Stem Cell 5, 204-13
19664994   Curated Info

42

Gauci S, et al. (2009) Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem 81, 4493-501
19413330   Curated Info

43

Nagano K, et al. (2009) Phosphoproteomic analysis of distinct tumor cell lines in response to nocodazole treatment. Proteomics 9, 2861-74
19415658   Curated Info

44

Possemato A (2009) CST Curation Set: 6371; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSP
Curated Info

45

Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46
19690332   Curated Info

46

Daub H, et al. (2008) Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell 31, 438-48
18691976   Curated Info

47

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info

48

Stokes M (2008) CST Curation Set: 4391; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

49

Ruse CI, et al. (2008) Motif-specific sampling of phosphoproteomes. J Proteome Res 7, 2140-50
18452278   Curated Info

50

Stokes M (2008) CST Curation Set: 3884; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

51

Imami K, et al. (2008) Automated Phosphoproteome Analysis for Cultured Cancer Cells by Two-Dimensional NanoLC-MS Using a Calcined Titania/C18 Biphasic Column. Anal Sci 24, 161-6
18187866   Curated Info

52

Beausoleil SA, et al. (2006) A probability-based approach for high-throughput protein phosphorylation analysis and site localization. Nat Biotechnol 24, 1285-92
16964243   Curated Info

53

Beausoleil SA, et al. (2004) Large-scale characterization of HeLa cell nuclear phosphoproteins. Proc Natl Acad Sci U S A 101, 12130-5
15302935   Curated Info